Masoud Tavazoie, Inspirna CEO
July 11, 2022 11:10 AM EDTUpdated 11:31 AM
Financing

Up­dat­ed: Dif­fer­ent way to go af­ter KRAS mu­tant tu­mors? No­vo-backed biotech nabs $50M to wrap ear­ly stud­ies

Amber Tong

Am­gen and Mi­rati may be duk­ing it out over who gets to set the stan­dard of care in KRAS mu­tant can­cer, but a small com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times